HTG Molecular Diagnostics (NASDAQ:HTGM) was upgraded by Zacks Investment Research from a “hold” rating to a “buy” rating in a report issued on Wednesday. The firm presently has a $3.75 price target on the medical research company’s stock. Zacks Investment Research‘s price target would indicate a potential upside of 1.08% from the stock’s current price.
According to Zacks, “HTG Molecular Diagnostics, Inc. is engaged in developing and marketing a technology platform which consists of instrumentation, consumables and software analytics for sample profiling applications including tumor profiling, molecular diagnostic testing and biomarker development. Its products include HTG Edge System, HTG Edge Assays and HTG Assay Direct. HTG Molecular Diagnostics, Inc. is headquartered in Tucson, Arizona. “
A number of other research firms also recently commented on HTGM. Canaccord Genuity increased their price objective on shares of HTG Molecular Diagnostics to $5.00 in a report on Friday, January 5th. HC Wainwright set a $6.00 price target on shares of HTG Molecular Diagnostics and gave the stock a “buy” rating in a report on Friday, January 5th. Finally, ValuEngine upgraded shares of HTG Molecular Diagnostics from a “strong sell” rating to a “sell” rating in a report on Monday, October 23rd. One equities research analyst has rated the stock with a sell rating, two have given a hold rating and two have issued a buy rating to the company’s stock. The stock presently has an average rating of “Hold” and an average price target of $5.19.
A hedge fund recently raised its stake in HTG Molecular Diagnostics stock. Vanguard Group Inc. lifted its position in shares of HTG Molecular Diagnostics Inc (NASDAQ:HTGM) by 38.9% in the second quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 135,234 shares of the medical research company’s stock after buying an additional 37,841 shares during the period. Vanguard Group Inc. owned approximately 1.42% of HTG Molecular Diagnostics worth $359,000 as of its most recent filing with the Securities and Exchange Commission (SEC). Hedge funds and other institutional investors own 15.15% of the company’s stock.
ILLEGAL ACTIVITY WARNING: This piece of content was originally posted by Community Financial News and is owned by of Community Financial News. If you are accessing this piece of content on another domain, it was illegally copied and republished in violation of U.S. and international trademark & copyright law. The legal version of this piece of content can be viewed at https://www.com-unik.info/2018/01/12/htg-molecular-diagnostics-htgm-upgraded-to-buy-by-zacks-investment-research.html.
About HTG Molecular Diagnostics
HTG Molecular Diagnostics, Inc is a commercial-stage company that develops and markets a technology platform to facilitate the routine use of complex molecular profiling. The Company’s HTG Edge and HTG EdgeSeq platforms, consisting of instrumentation, consumables and software analytics, are used in sample profiling applications, including tumor profiling, molecular diagnostic testing and biomarker development.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
What are top analysts saying about HTG Molecular Diagnostics? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for HTG Molecular Diagnostics and related companies.